On Tuesday, Shares of Alibaba Group Holding Limited (NYSE:BABA), lost -0.16% to $82.54.
Alibaba Group Holding, declared an upgrade of its Trade Assurance program, a free service designed to give businesses peace of mind when buying from overseas suppliers. With the upgrade, buyers who make purchases from qualified Alibaba.com suppliers will be entitled to up to a full refund of their deposits or order amounts should suppliers fail to meet the shipping times or product quality specified in contracts. Coverage has been extended to post delivery, meaning buyers are now entitled to full refunds in relevant transactions if they spot quality problems after receiving orders.
Through the upgraded service, Alibaba.com is bidding to boost trust in international trading over the Internet. “By providing maximum trade protection, Alibaba.com aims to make cross-border trading easier, therefore empowering small-and medium-sized businesses to engage in global trading,” said Wu Min Zhi, Senior Vice President, Alibaba Group. “By lessening concerns and building trust in international trade, we are committed to introducing more trade opportunities to Alibaba.com members. As a result, small and medium-sized businesses will not miss out the benefits of international trading due to trust concerns over product quality or payment security.”
Alibaba Group Holding Limited, through its auxiliaries, operates as an online and mobile commerce company in the People’s Republic of China and internationally.
Shares of Newmont Mining Corporation (NYSE:NEM), inclined 3.19% to $18.74, during its last trading session.
Newmont Mining Corporation, declared its Board of Directors declared a quarterly dividend of $0.025 per share of common stock, payable on September 24, 2015, to holders of record at the close of business on September 10, 2015. The average London Bullion Market Association (LBMA) P.M. Gold Price during the second quarter fell below the Company’s gold price linked dividend policy threshold of $1,200 per ounce. The Board of Directors authorized the Company to maintain the dividend for the third quarter based on strong year-to-date operating and financial performance.
The declaration and payment of dividends remains at the discretion of the Board of Directors and will depend on the Company’s financial results, cash requirements, future prospects and other factors deemed relevant by the Board.
Newmont Mining Corporation operates in the mining industry. It primarily acquires, develops, explores for, and produces gold, copper, and silver deposits. The company’s operations and/or assets are located in the United States, Australia, Peru, Indonesia, Ghana, and New Zealand.
Finally, Sequenom Inc. (NASDAQ:SQNM), ended its last trade with 1.96% gain, and closed at $3.12.
Sequenom Laboratories, a wholly owned partner of Sequenom, Inc. (SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, declared the forthcoming launch of the MaterniT™ GENOME laboratory-developed test. This test is the first noninvasive prenatal test (NIPT) to provide karyotype-level insight into fetal chromosomal status preceding to considering an invasive procedure. The MaterniT GENOME test adds genome-wide identification of chromosomal gains or losses greater than 7 megabases (Mb) in size to Sequenom Laboratories’ growing NIPT testing portfolio.
The MaterniT GENOME test builds upon the industry leading microdeletion performance demonstrated by Sequenom Laboratories with the MaterniT21 PLUS laboratory-developed test, which was recently highlighted in an article by Hume JH, et al, published in the peer-reviewed journal Prenatal Diagnosis. Data supporting the validation of the MaterniT GENOME test will be presented at the 19th International Conference on Prenatal Diagnosis and Treatment (sponsored by the International Society of Prenatal Diagnosis and Therapy - ISPD) in Washington D.C., taking place July 12-15, 2015. The MaterniT GENOME test will be accessible to physicians later this quarter.
Sequenom, Inc., a life sciences company, develops and commercializes molecular diagnostics testing services for the women’s health and oncology markets in the United States and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
